Labcorp — Apr 29, 2025 release

billion ◦ Diluted EPS: $2.52 versus $2.69 ◦ Adjusted EPS: $3.84 versus $3.68 • Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: ◦ Revenue guidance of 6.7% to 8.0% ◦ Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 ◦ Free Cash Flow of $1.10 billion to $1.25 billion • Providing broader access to comprehensive testing and laboratory services with several transactions announced/completed year-to-date • Introduced new tests including Labcorp Plasma Complete, a liquid biopsy test for cancer, and pTau-217/Beta Amyloid 42 Ratio test to aid in the diagnosis of Alzheimer's disease BURLINGTON, N.C., April 29, 2025 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance. “Labcorp delivered solid performance in the first quarter of 2025,” said Adam Schechter, chairman and CEO of Labcorp. “While the macroeconomic environment remains dynamic, the critical nature of the work we do in diagnostics and drug development positions us well for success in 2025 and beyond. We continue to progress our pipeline of attractive acquisitions and partnerships and further expand our test menu in four strategic areas, including oncology, women’s health, autoimmune disease and neurology.” 1 In the first quarter, Labcorp advanced its position as a partner of choice for ho